Advertisement
Screener

Humacyte, Inc. (HUMA) Gross Margin

Humacyte, Inc. (HUMA) Gross Margin

  • Gross margin · 12 months: Value (m); Formula and calculation Gross profit / revenue. Period ending 2026-06-30..

Gross margin

Overview →

Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.

MetricValueFormula and calculation
Gross margin · 12 months(m)Gross profit / revenue. Period ending 2026-06-30.

Calculation unavailable: missing inputs remain (m).

Calculation inputs

InputAmount with unitRaw financial data
Gross profit(m)
Revenue2.12M USDRevenue from Contract with Customer, Excluding Assessed Tax
Cost of products and services12.61M USDCost of Goods and Services Sold

Calculated history

Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.

Period endingGross profit (USD)Revenue (USD)Cost of products and services (USD)Gross margin
2026-06-30(m)$2.12M$12.61M(m)
2026-03-31(m)$2.02M$11.59M(m)
2025-12-31(m)$2.04M$9.70M(m)
2025-09-30(m)(m)(m)(m)
2025-06-30(m)(m)(m)(m)
2025-03-31(m)(m)(m)(m)
2024-12-31(m)$0.00$0.00(m)
2024-09-30(m)(m)(m)(m)
2024-06-30(m)(m)(m)(m)
2024-03-31(m)(m)(m)(m)

(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.

Similar stocks

Stock NameCountryMarket CapPE Ratio
Outlook Therapeutics, Inc. (OTLK)United States$0.162B-4.90
Acumen Pharmaceuticals, Inc. (ABOS)United States$0.162B-1.83
Tenaya Therapeutics, Inc. (TNYA)United States$0.140B-1.60
Voyager Therapeutics, Inc. (VYGR)United States$0.173B-1.99
PRECISION BIOSCIENCES INC (DTIL)United States$0.175B-3.95
Caribou Biosciences, Inc. (CRBU)United States$0.134B-1.79
Armata Pharmaceuticals, Inc. (ARMP)United States$0.132B
Neumora Therapeutics, Inc. (NMRA)United States$0.132B-1.48
enGene Therapeutics Inc. (ENGN)$0.129B-0.92
Coherus Oncology, Inc. (CHRS)United States$0.182B-1.63